WO2026064480A1 - Méthode et composition pour le traitement de maladies pulmonaires - Google Patents

Méthode et composition pour le traitement de maladies pulmonaires

Info

Publication number
WO2026064480A1
WO2026064480A1 PCT/US2025/046923 US2025046923W WO2026064480A1 WO 2026064480 A1 WO2026064480 A1 WO 2026064480A1 US 2025046923 W US2025046923 W US 2025046923W WO 2026064480 A1 WO2026064480 A1 WO 2026064480A1
Authority
WO
WIPO (PCT)
Prior art keywords
nintedanib
dose
dry powder
pharmaceutical composition
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2025/046923
Other languages
English (en)
Inventor
Wassim H. FARES
Jr. John J. Freeman
Michael CASTAGNA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mannkind Corp
Original Assignee
Mannkind Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mannkind Corp filed Critical Mannkind Corp
Publication of WO2026064480A1 publication Critical patent/WO2026064480A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une méthode, une composition et un kit pour le traitement de maladies pulmonaires causées par des radiations, des produits chimiques, des maladies et d'autres conditions. La méthode utilise un produit de combinaison pour inhalation comprenant une quantité thérapeutique d'une formulation de poudre sèche fournie dans un inhalateur devant être administrée à un sujet en ayant besoin par inhalation orale. La composition comprend des particules de dicétopipérazine et un inhibiteur de kinase pour inhalation orale.
PCT/US2025/046923 2024-09-18 2025-09-18 Méthode et composition pour le traitement de maladies pulmonaires Pending WO2026064480A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202463696304P 2024-09-18 2024-09-18
US63/696,304 2024-09-18

Publications (1)

Publication Number Publication Date
WO2026064480A1 true WO2026064480A1 (fr) 2026-03-26

Family

ID=99168089

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2025/046923 Pending WO2026064480A1 (fr) 2024-09-18 2025-09-18 Méthode et composition pour le traitement de maladies pulmonaires

Country Status (1)

Country Link
WO (1) WO2026064480A1 (fr)

Similar Documents

Publication Publication Date Title
Labiris et al. Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications
JP2024028720A (ja) エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用
KR20120131245A (ko) 기관지 감염의 치료 방법
KR20160141776A (ko) 연령 관련 병태를 치료하기 위한 흡입가능한 라파마이신 제제
US9248110B2 (en) Compositions and methods of treating and preventing lung cancer and lymphangioleiomyomatosis
CN110381951A (zh) 用于治疗肺性高血压和其他肺病症的方法及组合物
AU2003273273C1 (en) Trospium containing compositions
KR20170095807A (ko) 폐 고혈압의 치료를 위한 흡입가능 라파마이신 제제
US20250228779A1 (en) Method and composition for treating pulmonary fibrosis
Kaur et al. Advanced aerosol delivery devices for potential cure of acute and chronic diseases
CA3063436A1 (fr) Methodes de traitement de troubles pulmonaires
US20190321290A1 (en) Composition and method for inhalation
Dongare et al. An overview of recently published patents on pulmonary drug delivery devices
US20130291860A1 (en) Method For Treating Cystic Fibrosis with Inhaled Denufosol
US20240180897A1 (en) Methods and compositions for treating pulmonary hypertension
WO2026064480A1 (fr) Méthode et composition pour le traitement de maladies pulmonaires
AU2021263580A1 (en) Clofazimine composition and method for the treatment or prophylaxis of viral infections
US20250352530A1 (en) Method and composition for treating lung diseases
US20250288515A1 (en) Method and composition for treating lung diseases
Xie et al. Disease guided optimization of the respiratory delivery of microparticulate formulations
TW202612690A (zh) 用於治療肺疾病之方法及化合物
RU2773750C2 (ru) Способы лечения нарушений легких
HK40096956A (zh) 治疗肺纤维化的方法和组合物